Loss of BMPR2 leads to high bone mass due to increased osteoblast activity

Journal of Cell Science

Volumn 128, Issue 7, 2015, Pages 1308-1315

  Lowery, Jonathan W ^a,b   Intini, Giuseppe ^b   Gamer, Laura ^b   Lotinun, Sutada ^b,c   Salazar, Valerie S ^b   Ote, Satoshi ^b   Cox, Karen ^b   Baron, Roland ^b   Rosen, Vicki ^b  

^a IN   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Activin; BMP; BMPR2; Bone mass; Osteoblast; Osteoporosis

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ACTIVIN RECEPTOR 2; BMPR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MASS; CELL ACTIVITY; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BONE; BONE DEVELOPMENT; BONE DISEASE; CELL CULTURE; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

MUS;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE DISEASES; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; OSTEOBLASTS; SIGNAL TRANSDUCTION;

EID: 84928680419     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.156737     Document Type: Article

References (80)

1. Allendorph, G. P., Vale, W. W. and Choe, S. (2006). Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc. Natl. Acad. Sci. USA 103, 7643-7648.
2. Almeida, M., Iyer, S., Martin-Millan, M., Bartell, S. M., Han, L., Ambrogini, E., Onal, M., Xiong, J., Weinstein, R. S., Jilka, R. L. et al. (2013). Estrogen receptor-a signaling in osteoblast progenitors stimulates cortical bone accrual. J. Clin. Invest. 123, 394-404.
3. Alves, R. D., Eijken, M., Bezstarosti, K., Demmers, J. A. and van Leeuwen, J. P. (2013). Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix composition and impairing matrix vesicle production. Mol. Cell. Proteomics 12, 2890-2900.
4. Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S. and Sherman, M. L. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47, 416-423.
5. Baccarelli, A., Morpurgo, P. S., Corsi, A., Vaghi, I., Fanelli, M., Cremonesi, G., Vaninetti, S., Beck-Peccoz, P. and Spada, A. (2001). Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp. Gerontol. 36, 1403-1412.
6. Bakker, A. and Klein-Nulend, J. (2003). Osteoblast isolation from murine calvariae and long bones. Methods Mol. Med. 80, 19-28.
7. Beppu, H., Lei, H., Bloch, K. D. and Li, E. (2005). Generation of a floxed allele of the mouse BMP type II receptor gene. Genesis 41, 133-137.
8. Berasi, S. P., Varadarajan, U., Archambault, J., Cain, M., Souza, T. A., Abouzeid, A., Li, J., Brown, C. T., Dorner, A. J., Seeherman, H. J. et al. (2011). Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent of receptor binding affinities. Growth Factors 29, 128-139.
9. Bialek, P., Parkington, J., Li, X., Gavin, D., Wallace, C., Zhang, J., Root, A., Yan, G., Warner, L., Seeherman, H. J. et al. (2013). A myostatin and activin decoy receptor enhances bone formation in mice. Bone 60,162-171.
10. Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J. and Muller, R. (2010). Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468-1486.
11. Cadena, S. M., Tomkinson, K. N., Monnell, T. E., Spaits, M. S., Kumar, R., Underwood, K. W., Pearsall, R. S. and Lachey, J. L. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J. Appl. Physiol. 109, 635-642.
12. Candia, A. F., Watabe, T., Hawley, S. H., Onichtchouk, D., Zhang, Y., Derynck, R., Niehrs, C. and Cho, K. W. (1997). Cellular interpretation of multiple TGF-beta signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 124, 4467-4480.
13. Daly, R. and Hearn, M. T. (2006). Expression of the human activin type I and II receptor extracellular domains in Pichia pastoris. Protein Expr. Purif. 46, 456-467.
14. de Kretser, D. M., O'Hehir, R. E., Hardy, C. L. and Hedger, M. P. (2011). The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. 359, 101-106.
15. Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R. and Parfitt, A. M. (2013). Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2-17.
16. Durland, J. L., Sferlazzo, M., Logan, M. and Burke, A. C. (2008). Visualizing the lateral somitic frontier in the Prx1Cre transgenic mouse. J. Anat. 212, 590-602.
17. Eijken, M., Swagemakers, S., Koedam, M., Steenbergen, C., Derkx, P., Uitterlinden, A. G., van der Spek, P. J., Visser, J. A., de Jong, F. H., Pols, H. A. et al. (2007). The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 21, 2949-2960.
18. Fajardo, R. J., Manoharan, R. K., Pearsall, R. S., Davies, M. V., Marvell, T., Monnell, T. E., Ucran, J. A., Pearsall, A. E., Khanzode, D., Kumar, R. et al. (2010). Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46, 64-71.
19. Gamer, L. W., Tsuji, K., Cox, K., Capelo, L. P., Lowery, J., Beppu, H. and Rosen, V. (2011). BMPR-II is dispensable for formation of the limb skeleton. Genesis 49, 719-724.
20. Goumans, M. J., Lebrin, F. and Valdimarsdottir, G. (2003). Controlling the angiogenic switch: a balance between two distinct TGF-β receptor signaling pathways. Trends Cardiovasc. Med. 13, 301-307.
21. Greenwald, J., Groppe, J., Gray, P., Wiater, E., Kwiatkowski, W., Vale, W. and Choe, S. (2003). The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 11, 605-617.
22. Greenwald, J., Vega, M. E., Allendorph, G. P., Fischer, W. H., Vale, W. and Choe, S. (2004). A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol. Cell 15, 485-489.
23. Han, C., Hong, K. H., Kim, Y. H., Kim, M. J., Song, C., Kim, M. J., Kim, S. J., Raizada, M. K. and Oh, S. P. (2013). SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension. Hypertension 61, 1044-1052.
24. Harada, K., Shintani, Y., Sakamoto, Y., Wakatsuki, M., Shitsukawa, K. and Saito, S. (1996). Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. 81, 2125-2130.
25. Heinecke, K., Seher, A., Schmitz, W., Mueller, T. D., Sebald, W. and Nickel, J. (2009). Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biol. 7, 59.
26. Hinck, A. P. (2012). Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily. FEBS Lett. 586, 1860-1870.
27. Hu, J., Duppatla, V., Harth, S., Schmitz, W. and Sebald, W. (2010). Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues. Bioconjug. Chem. 21, 1762-1772.
28. Hurwitz, J. M. and Santoro, N. (2004). Inhibins, activins, and follistatin in the aging female and male. Semin. Reprod. Med. 22, 209-217.
29. Ikenoue, T., Jingushi, S., Urabe, K., Okazaki, K. and Iwamoto, Y. (1999). Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J. Cell. Biochem. 75, 206-214.
30. Isaacs, M. J., Kawakami, Y., Allendorph, G. P., Yoon, B. H., Izpisua Belmonte, J. C. and Choe, S. (2010). Bone morphogenetic protein-2 and -6 heterodimer illustrates the nature of ligand-receptor assembly. Mol. Endocrinol. 24, 1469-1477.
31. Izumi, N., Mizuguchi, S., Inagaki, Y., Saika, S., Kawada, N., Nakajima, Y., Inoue, K., Suehiro, S., Friedman, S. L. and Ikeda, K. (2006). BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am. J. Physiol. 290, L120-L126.
32. Kirsch, T., Nickel, J. and Sebald, W. (2000). BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 19, 3314-3324.
33. Knaus, P. and Sebald, W. (2001). Cooperativity of binding epitopes and receptor chains in the BMP/TGFbeta superfamily. Biol. Chem. 382, 1189-1195.
34. Kolanczyk, M., Kossler, N., Kühnisch, J., Lavitas, L., Stricker, S., Wilkening, U., Manjubala, I., Fratzl, P., Spörle, R., Herrmann, B. G. et al. (2007). Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16,874-886.
35. Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B. et al. (2010). A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology 151, 4289-4300.
36. Koncarevic, A., Kajimura, S., Cornwall-Brady, M., Andreucci, A., Pullen, A., Sako, D., Kumar, R., Grinberg, A. V., Liharska, K., Ucran, J. A. et al. (2012). A novel therapeutic approach to treating obesity through modulation of TGFβ signaling. Endocrinology 153, 3133-3146.
37. Lee, S. J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J. et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA 102, 18117-18122.
38. Lee, S. J., Huynh, T. V., Lee, Y. S., Sebald, S. M., Wilcox-Adelman, S. A., Iwamori, N., Lepper, C., Matzuk, M. M. and Fan, C. M. (2012). Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proc. Natl. Acad. Sci. USA 109, E2353-E2360.
39. Li, S., Meyer, N. P., Quarto, N. and Longaker, M. T. (2013). Integration of multiple signaling regulates through apoptosis the differential osteogenic potential of neural crest-derived and mesoderm-derived Osteoblasts. PLoS ONE 8, e58610.
40. Liu, H., Zhang, R., Chen, D., Oyajobi, B. O. and Zhao, M. (2012). Functional redundancy of type II BMP receptor and type IIB activin receptor in BMP2-induced osteoblast differentiation. J. Cell. Physiol. 227, 952-963.
41. Logan, M., Martin, J. F., Nagy, A., Lobe, C., Olson, E. N. and Tabin, C. J. (2002). Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33, 77-80.
42. Lotinun, S., Pearsall, R. S., Davies, M. V., Marvell, T. H., Monnell, T. E., Ucran, J., Fajardo, R. J., Kumar, R., Underwood, K. W., Seehra, J. et al. (2010). A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46, 1082-1088.
43. Lowery, J. W. and de Caestecker, M. P. (2010). BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 21, 287-298.
44. Massagué, J. (2012). TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630.
45. Matsumoto, Y., Otsuka, F., Hino, J., Miyoshi, T., Takano, M., Miyazato, M., Makino, H. and Kangawa, K. (2012). Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol. Cell. Endocrinol. 350, 78-86.
46. Mishina, Y., Starbuck, M. W., Gentile, M. A., Fukuda, T., Kasparcova, V., Seedor, J. G., Hanks, M. C., Amling, M., Pinero, G. J., Harada, S. et al. (2004). Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J. Biol. Chem. 279, 27560-27566.
47. Moerman, E. J., Teng, K., Lipschitz, D. A. and Lecka-Czernik, B. (2004). Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3, 379-389.
48. Morrell, N. W., Yang, X., Upton, P. D., Jourdan, K. B., Morgan, N., Sheares, K. K. and Trembath, R. C. (2001). Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β(1) and bone morphogenetic proteins. Circulation 104, 790-795.
49. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. and Luo, L. (2007). A global double-fluorescent Cre reporter mouse. Genesis 45, 593-605.
50. Nguyen, T. Q. and Goldschmeding, R. (2008). Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm. Res. 25, 2416-2426.
51. Nicks, K. M., Perrien, D. S., Akel, N. S., Suva, L. J. and Gaddy, D. (2009). Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol. Cell. Endocrinol. 310, 11-20.
52. Ohsawa, Y., Hagiwara, H., Nakatani, M., Yasue, A., Moriyama, K., Murakami, T., Tsuchida, K., Noji, S. and Sunada, Y. (2006). Muscular atrophy of caveolin-3-deficient mice is rescued by myostatirandomized, double-blind,n inhibition. J. Clin. Invest. 116, 2924-2934.
53. Oshimori, N. and Fuchs, E. (2012). Paracrine TGF-β signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell 10, 63-75.
54. Pearsall, R. S., Canalis, E., Cornwall-Brady, M., Underwood, K. W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E. D. et al. (2008). A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. USA 105, 7082-7087.
55. Perrien, D. S., Akel, N. S., Edwards, P. K., Carver, A. A., Bendre, M. S., Swain, F. L., Skinner, R. A., Hogue, W. R., Nicks, K. M., Pierson, T. M. et al. (2007). Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 148, 1654-1665.
56. Piek, E., Afrakhte, M., Sampath, K., van Zoelen, E. J., Heldin, C. H. and ten Dijke, P. (1999). Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J. Cell. Physiol. 180, 141-149.
57. Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J. and Attisano, L. (2003). Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230-7242.
58. Rosenzweig, B. L., Imamura, T., Okadome, T., Cox, G. N., Yamashita, H., ten Dijke, P., Heldin, C. H. and Miyazono, K. (1995). Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA 92, 7632-7636.
59. Ruckle, J., Jacobs, M., Kramer, W., Pearsall, A. E., Kumar, R., Underwood, K. W., Seehra, J., Yang, Y., Condon, C. H. and Sherman, M. L. (2009). Singledose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIAIgG1) in postmenopausal women. J. Bone Miner. Res. 24, 744-752.
60. Saitoh, M., Shirakihara, T., Fukasawa, A., Horiguchi, K., Sakamoto, K., Sugiya, H., Beppu, H., Fujita, Y., Morita, I., Miyazono, K. et al. (2013). Basolateral BMP signaling in polarized epithelial cells. PLoS ONE 8, e62659.
61. Sakai, R., Eto, Y., Hirafuji, M. and Shinoda, H. (2000). Activin release from bone coupled to bone resorption in organ culture of neonatal mouse calvaria. Bone 26, 235-240.
62. Sako, D., Grinberg, A. V., Liu, J., Davies, M. V., Castonguay, R., Maniatis, S., Andreucci, A. J., Pobre, E. G., Tomkinson, K. N., Monnell, T. E. et al. (2010). Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 285, 21037-21048.
63. Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A. et al. (2013). BMP signaling controls muscle mass. Nat. Genet. 45, 1309-1318.
64. Sengle, G., Ono, R. N., Lyons, K. M., Bächinger, H. P. and Sakai, L. Y. (2008). A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7. J. Mol. Biol. 381, 1025-1039.
65. Sherman, M. L., Borgstein, N. G., Mook, L., Wilson, D., Yang, Y., Chen, N., Kumar, R., Kim, K. and Laadem, A. (2013). Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J. Clin. Pharmacol. 53, 1121-1130.
66. Simic, P., Culej, J. B., Orlic, I., Grgurevic, L., Draca, N., Spaventi, R. and Vukicevic, S. (2006). Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J. Biol. Chem. 281, 25509-25521.
67. Stumm, C. L., Halcsik, E., Landgraf, R. G., Camara, N. O., Sogayar, M. C. and Jancar, S. (2014). Lung remodeling in a mouse model of asthma involves a balance between TGF-β1 and BMP-7. PLoS ONE 9, e95959.
68. Suragani, R. N., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S. et al. (2014). Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat. Med. 20, 408-414.
69. Syftestad, G. T. and Urist, M. R. (1982). Bone aging. Clin. Orthop. Relat. Res. 162,288-297.
70. Ueland, T., Aukrust, P., Aakhus, S., Smith, C., Endresen, K., Birkeland, K. I., Gullestad, L. and Johansen, O. E. (2012). Activin A and cardiovascular disease in type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 9, 234-237.
71. Wang, Q. and McPherron, A. C. (2012). Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. J. Physiol. 590, 2151-2165.
72. Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J. et al. (2013). The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J. Cell Biol. 203, 345-357.
73. Wordinger, R. J., Fleenor, D. L., Hellberg, P. E., Pang, I. H., Tovar, T. O., Zode, G. S., Fuller, J. A. and Clark, A. F. (2007). Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 48, 1191-1200.
74. Yamamoto, M., Beppu, H., Takaoka, K., Meno, C., Li, E., Miyazono, K. and Hamada, H. (2009). Antagonism between Smad1 and Smad2 signaling determines the site of distal visceral endoderm formation in the mouse embryo. J. Cell Biol. 184, 323-334.
75. Zhang, F., Qiu, T., Wu, X., Wan, C., Shi, W., Wang, Y., Chen, J. G., Wan, M., Clemens, T. L. and Cao, X. (2009). Sustained BMP signaling in osteoblasts stimulates bone formation by promoting angiogenesis and osteoblast differentiation. J. Bone Miner. Res. 24, 1224-1233.
76. Zhao, M., Harris, S. E., Horn, D., Geng, Z., Nishimura, R., Mundy, G. R. and Chen, D. (2002). Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J. Cell Biol. 157, 1049-1060.
77. Zhao, L., Yee, M. and O'Reilly, M. A. (2013). Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-β and BMP signaling. Am. J. Physiol. 305, L409-L418.
78. Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S. et al. (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543.
79. Zi, Z., Chapnick, D. A. and Liu, X. (2012). Dynamics of TGF-β/Smad signaling. FEBS Lett. 586, 1921-1928.
80. Zode, G. S., Clark, A. F. and Wordinger, R. J. (2009). Bone morphogenetic protein 4 inhibits TGF-beta2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia 57, 755-766.